Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice

#868

Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.

Aim(s): To evaluate how 68Ga-PET-CT results affected therapeutic decisions.

Materials and methods: Medical records of NETs patients who underwent 68Ga-PET-CT were reviewed retrospectively between 2010-2013. The analysis included: general anatomopathology characterization of the tumor, results of previous studies, treatment decision before the study, reason to perform the study, findings and treatment decisions.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Castillo Mandon A

Authors: Pesce V, Castillo Mandon A, O'Connor J, Bestanti C, Eleta M,

Keywords: neuroendocrine tumors, 68ga-pet-ct, therapeutic management,